Most of the attention on psilocybin has gone to depression, end-of-life distress, and addiction, the conditions where the trials are biggest and the headlines loudest. But one of the earliest and most intriguing modern studies pointed somewhere else entirely, at a condition that fits the psychedelic theory almost too neatly, obsessive-compulsive disorder. Published in 2006 by Francisco Moreno and colleagues at the University of Arizona in the Journal of Clinical Psychiatry, it was a small, careful look at whether psilocybin could ease the symptoms of a disorder defined, more than almost any other, by being stuck. It came years before the famous trials, it has been somewhat overlooked since, and it deserves better, both for what it found and for the elegance of the idea behind it.
This article reads the Moreno study on its own terms, as an early, modest, and genuinely interesting probe into an unexpected use. OCD is in some ways the purest test of the central psychedelic hypothesis, that these substances help by loosening rigid, locked-in patterns, because OCD is rigidity made into an illness. That theoretical fit is part of what makes the study worth revisiting. The findings were preliminary, the sample tiny, the design early-generation, and none of that erases the value of a study that asked a sharp question well ahead of its time. Check the specifics against the original paper before publishing, since the figures and design are where these claims rest.
Why OCD is an unusually good test of the theory
To see why this study is more interesting than its modest size suggests, you have to understand what obsessive-compulsive disorder actually is, and why it lines up so precisely with the way psychedelics are thought to work. OCD is characterized by obsessions, intrusive and unwanted thoughts that arrive uninvited and will not leave, and compulsions, repetitive behaviors a person feels driven to perform to relieve the anxiety those thoughts produce. The hallmark is a particular kind of mental rigidity. The sufferer is locked into loops, the same intrusive thought triggering the same ritual, over and over, in a groove so deep that ordinary willpower cannot climb out of it. It is, in a real sense, a disorder of being stuck.
Now set that next to the central theory of how psychedelics work. Across the depression and addiction research, the recurring idea is that these substances help by temporarily loosening rigid, entrenched patterns of thought and behavior, opening a window of psychological flexibility in which stuck patterns might be revised. If that theory has any truth to it, then OCD, a condition that is almost the definition of a stuck pattern, is close to an ideal place to test it. The fit is so clean it is almost suspicious, since here is a substance hypothesized to loosen rigidity pointed at a disorder made of rigidity. A positive result would be a striking confirmation of the underlying mechanism, and even a hint of one would be theoretically meaningful well beyond OCD itself.
There is also an anecdotal thread that motivated the study. Over the years there had been scattered reports, observations, case histories, accounts from people with OCD who had taken psychedelics recreationally, suggesting that the drugs could temporarily relieve obsessive-compulsive symptoms. Anecdotes are not evidence, and the field rightly treats them with caution, but a consistent pattern of them is exactly the kind of thing that can point a researcher toward a hypothesis worth testing properly. Moreno and his colleagues took that scattered, informal signal and did the careful thing, bringing it into a controlled clinical setting to see whether it held up under scrutiny. That move, from anecdote to study, is how a hunch becomes science.
It is worth saying a little more about why the standard treatments for OCD leave room for a new approach, because that gap is what makes the question more than academic. The frontline treatments are a particular class of antidepressants, the SSRIs, often at higher doses than are used for depression, together with a specific kind of behavioral therapy that involves deliberately confronting the feared thoughts without performing the rituals. These help a great many people, and they are genuinely valuable. But they do not work for everyone, the behavioral therapy is demanding and not always available, and a meaningful fraction of people with OCD continue to struggle despite the best available care. As with treatment-resistant depression, that residue of people the standard tools fail is exactly where the case for investigating a different mechanism gets strong. A drug that worked through an entirely different route, loosening the rigid loops rather than adjusting serotonin levels over weeks, might reach some of the people the existing treatments leave behind.
There is a deeper theoretical attraction too, having to do with speed. The SSRIs used for OCD take weeks to work, the same slow climb they take in depression, and the behavioral therapy is a gradual, effortful process. The psychedelic hypothesis raises the tantalizing possibility of something faster, a treatment that might open a window of flexibility quickly rather than grinding the rigidity down over months. Whether that possibility is real is precisely what a study like Moreno's begins, very tentatively, to probe, and the acute symptom reductions it looked for were the first place such a fast-acting effect would show up if it existed at all.
What they actually did
The study was small and early, a proof-of-concept investigation rather than a definitive trial, and its job was the modest one of seeing whether the idea was worth taking further. It enrolled nine participants with obsessive-compulsive disorder, a tiny number even by the standards of pilot work, appropriate to a first cautious look at an untested question. These were people with diagnosed OCD, the condition established rather than self-reported, which matters for taking the results seriously as far as they go.
The design tested several different doses of psilocybin in each participant, given in a controlled, supervised setting. Rather than a single dose against a placebo, the study used a range of doses, from low to high, administered across separate sessions, which let the researchers look at whether any effect varied with dose, a useful thing to know early on. The sessions were conducted under careful supervision with monitoring, the standard safeguard for this kind of work, and the participants' obsessive-compulsive symptoms were measured before and after using an established, validated rating scale for OCD severity, so that any change could be tracked against a recognized yardstick rather than a subjective impression.
The outcome of interest was the change in OCD symptom severity in the hours following each dose. This is worth marking, because it shaped what the study could see. The measurements focused on the acute period, looking at whether obsessive-compulsive symptoms eased in the time after psilocybin was administered, rather than tracking long-term outcomes over weeks and months the way the later depression trials would. So the question the study was really equipped to answer was relatively narrow and immediate, does psilocybin acutely reduce OCD symptoms, which is the right first question for a proof-of-concept study even though it leaves the bigger questions of durability untouched.
What they found
The results were positive in an interesting and specific way. Participants showed reductions in obsessive-compulsive symptoms following psilocybin administration, and in some cases the reductions were substantial. The drug appeared to acutely ease the very symptoms that define the disorder, the obsessive thoughts and the compulsive urges, at least in the period following the dose. For a first controlled look at an untested idea, finding a clear acute effect on the target symptoms was a genuinely encouraging result, and it lent real support to the anecdotal reports that had motivated the study.
A particularly interesting wrinkle was that the symptom reductions did not appear to depend straightforwardly on dose in the way one might naively expect. Improvements were seen across the range of doses tested, including lower ones, rather than only at the highest dose. That detail is worth pausing on, because it hints that the mechanism behind any anti-OCD effect might not simply track the intensity of the psychedelic experience, which complicates the tidy story and, in doing so, makes it more interesting. If even modest doses could ease symptoms, the effect might run through something other than the full-blown subjective trip, a possibility that would have implications for how such a treatment might eventually be designed.
It is worth drawing out why that observation, if it holds, would matter so much, because it bears on one of the deepest open questions in the whole field. Much of the depression research has found that the depth of the subjective experience, the profound, meaning-saturated quality of a high-dose session, tends to track the therapeutic benefit, which has led many researchers to suspect that the experience itself is the active ingredient. The Moreno finding, that lower doses also helped with OCD, pulls gently in the opposite direction, raising the possibility that for some conditions the benefit might come from the drug's direct effect on brain circuits rather than from the dramatic conscious experience. If that were true, it would matter enormously for treatment design, since a therapy that worked at low, non-intoxicating doses would be far easier and cheaper to deliver than one requiring a full supervised trip. A tiny nine-person study cannot settle which picture is right, and the dose pattern it observed could be noise in such a small sample. But the question it raises, whether the trip is the medicine or merely the most visible sign of it, is among the most consequential the field has, and this early study brushed against it.
It is also worth being careful here, because the small sample makes the dose observation especially fragile. With only nine people spread across several doses, the number of participants at any given dose was vanishingly small, which means the apparent pattern of improvement across doses could easily be an artifact of which particular individuals responded rather than a real feature of how the drug works. The honest reading treats the dose finding as a provocative hint worth testing, not as an established fact, exactly the kind of lead a proof-of-concept study is meant to generate for others to chase.
Pull quote: OCD is rigidity made into an illness, and here was a drug hypothesized to loosen rigidity. The fit was almost too neat, which is exactly why a clear acute effect was worth taking seriously.
The safety picture, within this small and supervised study, was reassuring. The psilocybin was well tolerated by the participants, with no serious adverse events reported, and the acute symptom relief came without the kind of problems that would have halted the inquiry.
As with every study of this kind, that clean safety record belongs to a small, screened, closely monitored group, and it cannot be stretched to cover unsupervised use or a broader population. But for what it was, a careful first test, the study cleared the basic safety bar that any further work would depend on, while producing a symptom signal striking enough to justify that further work.
Where the study holds up
For a study of its size and era, the Moreno trial was thoughtfully constructed, and several of its choices deserve credit. Using an established, validated OCD rating scale meant the symptom changes were measured against a recognized standard rather than an ad hoc impression, which makes the findings easier to interpret and to compare with other OCD research. Testing a range of doses rather than a single one was a smart move for a proof-of-concept study, since it produced the genuinely interesting observation that improvement was not confined to the highest dose, a finding that pointed toward questions worth pursuing. And conducting the sessions under careful supervision with proper monitoring reflected appropriate caution for an early trial of a Schedule I substance in a clinical population.
The study also gets credit for its very subject, for pointing the psychedelic question at OCD at all, years before the field's attention consolidated around depression and addiction. Choosing a target so theoretically apt, a disorder of rigidity tested against a drug hypothesized to loosen rigidity, was an insightful piece of scientific reasoning, and translating the scattered anecdotal reports into a controlled investigation was exactly the responsible way to follow up an informal signal. The authors framed the work honestly as preliminary, a proof of concept rather than a demonstration of efficacy, which is the correct posture for a nine-person study and a sign of the integrity that makes the work trustworthy as far as it reaches. Published in a serious clinical psychiatry journal, it stood as a legitimate early contribution to a question the field would not fully return to for years.
Where it strains
The limits are substantial, and most of them are the familiar ones, sharpened by the study's small size and early date. The sample of nine is tiny, even for a pilot, which means the findings can be no more than suggestive and cannot support any confident claim about efficacy. With so few participants, individual variation looms large, and what looks like a clear effect could in part reflect the particular handful of people who happened to enroll. A study this small is built to detect whether an effect might be there at all, not to measure it reliably, and reading firm conclusions into nine people would misuse the data.
The focus on acute, short-term symptom change is another real limit. The study looked at what happened in the hours following each dose, which tells you whether psilocybin can transiently ease OCD symptoms but says little about whether any benefit lasts, and durability is the question that matters most for a chronic condition like OCD. A temporary reduction in symptoms during the post-dose window is interesting, but it is a long way from a lasting therapeutic effect, and this study was not designed to distinguish the two.
This distinction deserves a little weight, because it is easy to blur in the excitement of a positive result. Many things can transiently quiet OCD symptoms, including distraction, novelty, and the simple disruption of routine, and a powerful altered state is nothing if not disruptive. So an acute drop in symptoms during the hours after a psychedelic dose, while genuinely interesting, is not by itself strong evidence of a durable treatment effect, since it could reflect a temporary interruption of the obsessive loops rather than any lasting change to them. What would matter clinically is whether the loops stay loosened after the drug has cleared, days and weeks later, and that is exactly what an acute-focused study cannot see. The later depression trials made durability central precisely because a brief effect and a lasting one are so different, and the Moreno study, by its design, could only glimpse the first. That is not a flaw for a proof-of-concept probe, but it is a sharp limit on what the encouraging acute signal can be taken to mean.
The blinding situation was also limited in the way it tends to be in this work, since psilocybin's effects are hard to disguise, which leaves room for expectancy to color the results, especially in a study measuring symptoms the participants themselves experience. And the population, nine people with OCD who volunteered for a psychedelic study, is both small and selected, limiting how far the findings generalize. People willing to take psilocybin in a research setting to address their OCD may differ in important ways from the broader population of people with the disorder, in openness, in severity, in what other treatments they have tried, and a study this size cannot account for any of that. None of these criticisms is a surprise or a scandal. They are the expected limits of an early proof-of-concept study, and they locate the work correctly, as a promising first probe rather than a settled finding.
What it justifies, and what it does not
A measured reading is clear. What the Moreno 2006 study justifies is the conclusion that psilocybin showed a real, acute signal of reducing obsessive-compulsive symptoms in a small, supervised group, and that this signal, together with the strong theoretical fit and the prior anecdotal reports, makes OCD a target genuinely worth pursuing with larger and better-controlled trials. It justifies treating the underlying mechanism, the loosening of rigid patterns, as having found at least preliminary support in exactly the disorder where that mechanism would predict an effect. And it justifies the modest claim that the approach was safe and feasible enough in this small study to warrant going further.
What it does not justify is any claim that psilocybin has been shown to treat OCD, because a nine-person proof-of-concept study focused on acute effects cannot establish a treatment effect, and certainly cannot speak to lasting benefit. It does not justify citing the result as strong evidence, since it was preliminary by the authors' own honest framing. And it does not justify treating the absence of major follow-up over the years that followed as either confirmation or refutation, since the question simply has not yet received the larger trials it deserves. The honest reading is that the study found an intriguing early signal in a theoretically apt place, and that the signal remains, even now, more a promising lead than an established finding, awaiting the rigorous work that would settle it.
Why this study still matters
The Moreno 2006 study earns its place for a few reasons that outlast its modest size. It was among the earliest modern controlled investigations of psilocybin in a psychiatric population, predating the celebrated depression and cancer trials, and it did so by pointing at a target, OCD, that the field would not seriously return to for years. In that sense it was ahead of its time, asking a sharp question before the infrastructure and attention existed to answer it fully. The fact that it has been somewhat overlooked since says more about where the field's resources flowed, toward depression and addiction, than about the quality or interest of the question it raised.
It also stands as the cleanest test of the central psychedelic hypothesis the early literature offers, precisely because OCD is rigidity in its starkest clinical form. The recurring theory that these substances work by loosening locked-in patterns makes a specific prediction about OCD, and the Moreno study, however preliminary, found a result pointing in the predicted direction. That is theoretically meaningful in a way that reaches beyond OCD, since support for the mechanism in its purest test case lends some weight to the mechanism wherever else it is invoked.
It is worth dwelling on that logic, because it is a nice example of how a study can matter beyond its immediate subject. A general theory is most convincingly tested where it makes its sharpest, most specific prediction, and the loosening-rigidity theory makes about as sharp a prediction as it can make in OCD, a disorder that is essentially rigidity given a clinical name. When a theory survives a test that pointed, it earns a little more credibility everywhere else it is applied, including in depression and addiction, where the same mechanism is invoked but where the prediction is fuzzier because those conditions are not rigidity in such a pure form. So a small OCD study, almost paradoxically, can lend indirect support to the much larger body of depression research, not by studying depression but by stress-testing the shared idea underneath it in the place that idea is most exposed. That is a subtle kind of importance, easy to miss if you only count participants, and it is part of why the study deserves more attention than it has received.
There is also a lesson in the study's relative neglect, one about how research priorities get set. The fact that OCD was probed early and then largely set aside, while depression and addiction drew the bulk of the funding and attention, says little about the scientific merit of the OCD question and a great deal about the practical forces that steer a field, where the money is, which conditions have the largest patient populations and the strongest commercial interest, which results made the biggest headlines. None of those forces tracks theoretical interest very closely, and one consequence is that genuinely promising leads can sit undeveloped for years simply because the field's resources flowed elsewhere. The Moreno study is a case in point, an early, theoretically pointed result that has been waiting a long time for the follow-up it deserves.
The honest way to hold the study is as an early, careful, underdeveloped probe that asked one of the most theoretically pointed questions in the whole field and came back with an encouraging preliminary answer, an answer that has been waiting, ever since, for the larger trials it deserves to either confirm or complicate. Some of the most interesting questions in science are the ones that got asked early and then set aside, and this is one of them.